ClinicalTrials.gg
TerminatedNCT03603964Updated Aug 27, 2024Results posted

Guadecitabine Extension Study

A Phase 2 interventional study of Guadecitabine in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome, sponsored by Astex Pharmaceuticals, Inc.. Terminated at 21 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Early termination not due to patient safety

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. — 4 open to participants now, 6 under way, 2 of them phase 3. Leukemia, Myeloid, Acute · Otsuka Holdings Co., Ltd..

Enrollment
11th of 20
35 · median 42
Started
2018
with 2 others
Phase 2
3 of 20
1 open now
Registered
10th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 3 in phase 2, and was the 10th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

This is a multicenter, open-label extension study for participants who participated in a previous Astex-sponsored guadecitabine clinical study [including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)].

Read the detailed description

Participants who were still receiving treatment with guadecitabine and in the opinion of the investigator were still benefitting from treatment at the time of database close of the original study will be eligible to participate in this extension study. Approximately 250 subjects could be enrolled.

Participants will attend clinic visits on Days 1-5 of each 28-day cycle to receive treatment with guadecitabine. Data collection will be limited to treatment exposure, adverse events, concomitant medications, limited laboratory parameters, and survival status.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myeloid Dysplastic Syndrome

Keywords

  • Guadecitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previous participation in an Astex-sponsored guadecitabine clinical trial [including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT03603964), SGI-110-05, SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)], in which the participant was treated with guadecitabine and was still on active treatment with guadecitabine at the time of database close for the prior study.
  2. Participant is considered to be benefitting from guadecitabine treatment in the opinion of the treating investigator.
  3. Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written before any study-specific procedure.
  4. Women of (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective measures while receiving treatment with guadecitabine and for at least 3 months after completing treatment and must agree not to become pregnant or father a child while receiving study treatment and for at least 3 months after completing guadecitabine treatment.

Exclusion criteria

Exclusion Criteria:

    1. Any participant who, in the opinion of the investigator, may have other conditions, organ dysfunction, or have safety data from their prior study participation that suggest that the risks of continuing treatment with guadecitabine may outweigh the benefits.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Guadecitabine

    Participants received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.

    Drug: Guadecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs are defined as events that occur or worsen on or after the date of the first study treatment (Cycle 1 Day 1 {C1D1}) until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment, whichever occurs first.

    Time frame: From the start of study treatment until 30 days after the last dose of study treatment or prior to the participant receiving alternative anticancer therapy, whichever occurs first.

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the number of days from the time of randomization in the prior study to the date of death (regardless of cause). Participants without a documented death date at the time of analysis were censored at the last date known alive. Survival time in days = (earliest of date of death or censoring) - (randomization date in the prior study).

    Time frame: From randomization in the prior study to the date of death

07

Results

Posted Apr 26, 2023
Limitations and caveats
The study was terminated early not due to participant safety.

Participant flow

Participants were enrolled in the study at 32 study centers in the United States, Spain, Italy, Canada, Japan, France, Germany, Poland, Finland, South Korea, Taiwan, Czech Republic and Australia from 18 July 2018 to 30 November 2020.

Participant flow — Overall Study
MilestoneGuadecitabine
Started35
Completed0
Not completed35
Withdrew: Death9
Withdrew: Withdrawal by participant7
Withdrew: Study terminated by sponsor19

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs are defined as events that occur or worsen on or after the date of the first study treatment (Cycle 1 Day 1 {C1D1}) until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment, whichever occurs first.

Time frame:
From the start of study treatment until 30 days after the last dose of study treatment or prior to the participant receiving alternative anticancer therapy, whichever occurs first.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsGuadecitabine
Number of Participants With Treatment Emergent Adverse Events (TEAEs)31
SecondaryOverall Survival

Overall survival was defined as the number of days from the time of randomization in the prior study to the date of death (regardless of cause). Participants without a documented death date at the time of analysis were censored at the last date known alive. Survival time in days = (earliest of date of death or censoring) - (randomization date in the prior study).

Time frame:
From randomization in the prior study to the date of death
Reported as:
Median · days
Overall Survival
daysGuadecitabine
Overall Survival2583.0 (1422.0 to NA)

Adverse events

Collected over From the start of study treatment until 30 days after the last dose of study treatment or prior to the participant receiving alternative anticancer therapy, whichever occurs first.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Guadecitabine9/35 (25.7%)20/35 (57.1%)0/35 (0%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventGuadecitabine
Febrile neutropeniaBlood and lymphatic system disorders7/35
PneumoniaInfections and infestations6/35
SepsisInfections and infestations3/35
Upper gastrointestinal haemorrhageGastrointestinal disorders1/35
AstheniaGeneral disorders1/35
Anaphylactic reactionImmune system disorders1/35
Bronchopulmonary aspergillosisInfections and infestations1/35
Clostridium difficile colitisInfections and infestations1/35
GastroenteritisInfections and infestations1/35
Herpes zosterInfections and infestations1/35

Baseline characteristics

Efficacy population included all participants who received any amount of study treatment.

Age, Continuous
Age, Continuous(years)Guadecitabine
Mean75.3 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Guadecitabine
Female15
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Guadecitabine
Hispanic or Latino4
Not Hispanic or Latino29
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Guadecitabine
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White24
More than one race0
Unknown or Not Reported1
08

Study locations

21 sites
  • Roswell Park
    Buffalo, New York 14263, United States
  • Duke Cancer Center
    Durham, North Carolina 27705, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Temple University
    Philadelphia, Pennsylvania 19111, United States
  • Center for Blood Cancers
    Nashville, Tennessee 37203, United States
  • Medizinische Universität Graz
    Graz, Styria, Austria
  • The Ottawa Hospital - General
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G 2M9, Canada
  • Rigshospitalet-Copenhagen University Hospital
    Copenhagen, Denmark
  • Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
    Alessandria, Italy
  • Azienda Ospedaliera Universitaria San Martino
    Genova, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Italy
  • Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine
    Udine, Italy
  • Tokai University Hospital
    Isehara-shi, 259-1193, Japan
  • Japanese Red Cross Kyoto Daini Hospital
    Kyoto-shi, 602-8026, Japan
  • Saga University Hospital
    Saga-shi, 849-8501, Japan
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, 44033, Korea, Republic of
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Mackay Memorial Hospital
    Taipei, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Oct 2021, 38 months.

Results were first posted in Apr 2023, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2018
First posted
Jul 27, 2018
StartActual
Jul 18, 2018
Primary completionActual
Oct 4, 2021
CompletionActual
Oct 4, 2021
Results first posted
Apr 26, 2023
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03603964
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Jul 18, 2018
Primary completion
Oct 4, 2021
Completion
Oct 4, 2021
Results posted
Apr 26, 2023
Last update
Aug 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guadecitabine

Start the discussion